Anxiolytic-like effects of Kava-Kava in the elevated plus maze test - A comparison with diazepam

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 26, Issue 5, 2002, Pages 855-860

  Rex, A ^a   Morgenstern, Eve ^b   Fink, Heidrun ^a  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

^b Biopharm GmbH   (Germany)

Author keywords

Anxiety; Anxiolytic; Diazepam; Kava Kava extract LI 150; Rat; X maze

Indexed keywords

DIAZEPAM; KAVA;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY; ARTICLE; CONTROLLED STUDY; DOSE CALCULATION; DOSE RESPONSE; DRUG EFFECT; LOCOMOTION; MALE; MAZE TEST; NONHUMAN; RAT;

ANIMALS; ANTI-ANXIETY AGENTS; ANXIETY; DIAZEPAM; DOSE-RESPONSE RELATIONSHIP, DRUG; KAVA; MALE; MAZE LEARNING; PHYTOTHERAPY; PLANT EXTRACTS; PLANT ROOTS; RATS; RATS, WISTAR;

EID: 0036592357     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0278-5846(01)00330-X     Document Type: Article

References (40)

1. Ballinger B.R. Hypnotics and anxiolytics. Br. Med. J. 300:1990;456-458.
2. Beaubrun G., Gray G.E. A review of herbal medicines for psychiatric disorders. Psychiatr. Serv. 51:2000;1130-1134.
3. Boerner R.J., Berger W., Mannel N. Kava-Kava in der Therapie der generalisierten Angststörung. Nervenarzt. 71(Suppl. 1):2000;533.
4. Chopin P., Briley M. Animal models of anxiety: the effect of compounds that modify 5-HT neurotransmission. TIPS. 8:1987;383-388.
5. Costall B., Domeney A.M., Gerrard P.A., Kelly M.E., Naylor R.J. Zacopride: anxiolytic profile in rodent and primate models of anxiety. J. Pharm. Pharmacol. 40:1988;302-305.
6. Dalvi A., Rodgers R.J. Behavioral effects of diazepam in the murine plus-maze: flumazenil antagonism of enhanced head dipping but not the disinhibition of open-arm avoidance. Pharmacol., Biochem. Behav. 62:1999;727-734.
7. Fernandes C., Arnot M.I., Irvine E.E., Bateson A.N., Martin I.L., File S.E. The effect of treatment regimen on the development of tolerance to the sedative and anxiolytic effects of diazepam. Psychopharmacology. 145:1999;251-259.
8. Green S. Benzodiazepines, putative anxiolytics and animal models of anxiety. TIPS. 14:1991;101-104.
9. Griebel G. 5-Hydroxytryptamine-interacting drugs in animal models of anxiety disorders: more than 30 years of research. Pharmacol. Ther. 65:1995;319-395.
10. Guimaraes F.S., Chiaretti T.M., Graeff F.G., Zuardi A.W. Antianxiety effect of cannabidiol in the elevated plus-maze. Psychopharmacology. 100:1990;558-559.
11. Handley S.L., Mithani S. Effects of alpha-adrenoceptor agonists and antagonists in a maze-exploration model of "fear"-motivated behaviour. Naunyn-Schmiedeberg's Arch. Pharmacol. 327:1984;1-5.
12. Hogg S. A review of the validity and variability of the elevated plus-maze as an animal model of anxiety. Pharmacol., Biochem. Behav. 54:1996;21-30.
13. Holm M. Prescription of benzodiazepines in general practice in the county of Arhus, Denmark. Dan. Med. Bull. 35:1988;495-499.
14. Jones G.H., Schneider C., Schneider H.H., Seidler J., Cole B.J., Stephens D.N. Comparison of several benzodiazepine receptor ligands in two models of anxiolytic activity in the mouse: an analysis based on fractional receptor occupancies. Psychopharmacology. 114:1994;191-199.
15. Kinzler E., Kromer J., Lehmann E. Clinical efficacy of a kava extract in patients with anxiety syndrome. Double-blind placebo controlled study over 4 weeks. Arzneim.-Forsch./Drug Res. 41:1991;584-588.
16. Lader M. Animal models of anxiety: a clinical perspective. Willner P. Behavioural Models in Psychopharmacology: Theoretical, Industrial and Clinical Perspectives. 1991;76-88 Cambridge University Press, Cambridge.
17. Lader M.H. Limitations on the use of benzodiazepines in anxiety and insomnia: are they justified? Eur. Neuropsychopharmacol. 9(Suppl. 6):1999;399-405.
18. Lake J. Psychotropic medications from natural products: a review of promising research and recommendations. Altern. Ther. Health Med. 6:2000;36-45.
19. Lister R.G. The use of a plus-maze to measure anxiety in the mouse. Psychopharmacology. 92:1987;180-185.
20. Löscher W., Frey H.H. Pharmacokinetics of diazepam in the dog. Arch. Int. Pharmacodyn. Ther. 25:1981;180-195.
21. Malsch U., Kieser M. Efficacy of Kava-Kava in the treatment of non-psychotic anxiety, following pretreatment with benzodiazepines. Psychopharmacology. 157:2001;277-283.
22. Merlo-Pich E., Samanin R. A two-compartment exploratory model to study anxiolytic/anxiogenic effects of drugs in the rat. Pharmacol. Res. 21:1989;595-602.
23. Montgomery K.C. The relation between fear induced by novel stimulation and exploratory behaviour. J. Comp. Physiol. Psychol. 48:1955;254-260.
24. Pellow S., Chopin P., File S.E., Briley M. Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J. Neurosci. Methods. 14:1985;149-167.
25. Pellow S., File S.E. Anxiolytic and anxiogenic drug effects on exploratory activity in an elevated plus-maze: a novel test of anxiety in the rat. Pharmacol., Biochem. Behav. 24:1986;525-529.
26. Pittler M.H., Ernst E. Efficacy of kava extract for treating anxiety: systematic review and meta-analysis. J. Clin. Psychopharmacol. 20:2000;84-89.
27. Rang H.P., Dale M.M., Ritter J.M. Pharmacology. third ed. 1995;Churchill Livingstone, Edinburgh.
28. Rex A., Marsden C.A., Fink H. Effect of diazepam on cortical 5-HT release and behaviour in the guinea-pig on exposure to the elevated plus maze. Psychopharmacology. 110:1993;490-496.
29. Rex A., Stephens D.N., Fink H. "Anxiolytic" action of diazepam and abecarnil in a modified open field test. Pharmacol., Biochem. Behav. 53:1996;1005-1011.
30. Rex A., Voigt J.-P., Voits M., Fink H. Pharmacological evaluation of a modified open field test sensitive to anxiolytic drugs. Pharmacol., Biochem. Behav. 59:1998;677-683.
31. Rodgers R.J., Cole J.C. The elevated plus-maze: pharmacology, methodology and ethology. Cooper S.J., Hendrie C.A. Ethology and Psychopharmacology. 1994;9-44 Wiley, London.
32. Rodgers R.J., Johnson N.J. Factor analysis of spatiotemporal and ethological measures in the murine elevated plus-maze test of anxiety. Pharmacol., Biochem. Behav. 52:1995;297-303.
33. Rohmer J.G., Di Scala G., Sandner G. Behavioral analysis of the effects of benzodiazepine receptor ligands in the conditioned burying paradigm. Behav. Brain Res. 38:1990;45-54.
34. Schulz H., Jobert M., Hübner W.D. The quantitative EEG as a screening instrument to identify sedative effects of single doses of plant extracts in comparison with diazepam. Phytomedicine. 5:1998;449-458.
35. Smith K.K., Dharmaratne H.R., Feltenstein M.W., Broom S.L., Roach J.T., Nanayakkara N.P., Khan I.A., Sufka K.J. Anxiolytic effects of kava extract and kavalactones in the chick social separation-stress paradigm. Psychopharmacology. 155:2001;86-90.
36. Stephens D.N., Andrews J.S. Screening for anxiolytic drugs. Willner P. Behavioural Models in Psychopharmacology: Theoretical, Industrial and Clinical Perspectives. 1991;50-75 Cambridge University Press, Cambridge.
37. Taukulis H.K., Goggin C.E. Diazepam-stress interactions in the rat: effects on autoanalgesia and a plus-maze model of anxiety. Behav. Neural Biol. 53:1990;205-216.
38. Volz H.P., Kieser M. Kava-Kava extract WS 1490 versus placebo in anxiety disorders - a randomized placebo-controlled 25-week outpatient trial. Pharmacopsychiatry. 30:1997;1-5.
39. Woelk H., Kapoula O., Lehrl S., Schroter K., Weinholz P. Treatment of anxiety patients. Double-blind study: Kava special extract WS 1490 versus benzodiazepine. Z. Allgemeinmed. 69:1993;271-277.
40. Wright I.K., Upton N., Marsden C.A. Effect of established and putative anxiolytics on extracellular 5-HT and 5-HIAA in the ventral hippocampus of rats during behaviour on the elevated X-maze. Psychopharmacology. 109:1992;338-346.